Epoxidase inhibitor-aspirin resistance and the relationship with genetic polymorphisms: a review

Area of Science:

• Cardiovascular Science
• Pharmacogenomics
• Molecular Biology

Background:

• Strokes are a leading global cause of death, with aspirin (acetylsalicylic acid) widely used for prevention.
• Aspirin resistance, where patients still experience ischaemic events, hinders effective treatment and prevention strategies.
• Factors influencing aspirin resistance include genetics, drug dosage, and drug interactions.

Approach:

• This narrative review synthesizes current research on gene polymorphisms associated with aspirin resistance.
• The review focuses on how genetic variations in platelet receptors and aggregation pathways contribute to treatment failure.
• Analysis of existing literature to identify significant gene polymorphisms linked to aspirin resistance.

Key Points:

• Genetic polymorphism, the presence of multiple gene variants in a population, plays a crucial role in aspirin resistance.
• Polymorphisms in genes encoding platelet transmembrane glycoprotein receptors can alter platelet aggregation, leading to resistance.
• Specific gene polymorphisms have been identified as significantly associated with the development of aspirin resistance.

Conclusions:

• Understanding the mechanisms of aspirin resistance, particularly the role of gene polymorphisms, is essential for personalized medicine.
• Increased knowledge of pharmacogenomics can lead to more accurate drug guidance for individuals requiring antiplatelet therapy.
• Future research should focus on elucidating specific genetic markers to optimize aspirin treatment strategies.